Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.41 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15264642 | 0.78 | POLB (0.45) | POLBTTBK1TTBK2MAPTLMNA | |
| SCHEMBL27522307 | 0.75 | GRM4 (0.42) | POLBTTBK1TTBK2MAPTLMNA | |
| SCHEMBL15224220 | 0.74 | KDM4A (0.41) | POLBMAPK1AURKAPDPK1AURKB | |
| SCHEMBL2231249 | 0.74 | POLB (0.44) | POLBMAPTLMNAGAAHPGD | |
| SCHEMBL7215765 | 0.70 | NPY5R (0.47) | POLBTTBK1TTBK2LMNAHPGD | |
| Hydrochloric Acid SCHEMBL7215863 | 0.69 | PDE5A (0.47) | POLBTTBK1TTBK2LMNAHPGD | |
| SCHEMBL31338520 | 0.68 | CDK2 (0.42) | POLBTTBK1TTBK2MAPTGAA | |
| SCHEMBL31338519 | 0.68 | CDK2 (0.42) | POLBTTBK1TTBK2MAPTGAA | |
| SCHEMBL2037022 | 0.67 | DHODH (0.57) | TTBK1TTBK2MAPTGAAGRM4 | |
| SCHEMBL3915231 | 0.67 | BCAT2 (0.45) | POLBTTBK1TTBK2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608792-B1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20160287591-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| US-20130289056-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2608792-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| CN-102936251-A | Preparation method of pyrrolo[2,3-d]pyrimidine derivative | BEPHARM LTD | 2013-02-20 | — | — | CN | disclosed |
| CN-101827848-B | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC | 2012-11-07 | — | — | CN | disclosed |
| US-8198266-B2 | Use of an EGFR antagonist for the treatment of glomerolonephritis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-06-12 | — | — | US | disclosed |
| WO-2012027445-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
| CN-1830964-B | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof | SHANGHAI INST OF MEDICINES CHINESE ACADEMY OF SCIENCES | 2011-06-15 | — | — | CN | disclosed |
| CN-101827848-A | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | SMITHKLINE BEECHAM CORP | 2010-09-08 | — | — | CN | disclosed |
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | INSERM (INETITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE ) (FR) | 2010-04-29 | — | — | US | disclosed |
| WO-2009104027-A1 | THERAPEUTIC APPLICATION OF TRICICLIC AROMATIC AND SATURATED BENZO(4,5)THIENO-(2,3-D)PYRIMIDINE DERIVATES, AS WELL AS THEIR THERAPEUTICALLY ACCEPTABLE SALTS | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | disclosed |
| EP-2077842-A2 | USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2009-07-15 | — | — | EP | disclosed |
| CN-100432071-C | Substituted 1H-indole-2-ketone compound and its preparation method and uses | SHANGHAI INST MATERIA MEDICA (CN) | 2008-11-12 | — | — | CN | disclosed |
| WO-2008063773-A9 | COMBINATORIAL TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR MOLECULES AND MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 | UNIV COLUMBIA (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008063773-A2 | COMBINATORIAL TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR MOLECULES AND MELANOMA DIFFERENTIATION ASSOCIATED GENE-7 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008053270-A2 | USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2008-05-08 | — | — | WO | disclosed |
| CN-1958572-A | Compound in category of dihydro quinolines, preparation method, and composition of medication | SHANGHAI INST OF MEDICINE C A (CN) | 2007-05-09 | — | — | CN | disclosed |
| CN-1830964-A | 4-Substituting anilino-3-nitroquinoline compounds, prepn. method and use thereof | SHANGHAI INST OF MEDICINES CHI (CN) | 2006-09-13 | — | — | CN | disclosed |
| CN-1769284-A | Substituted 1H-indole-2-ketone compound and its preparation method and uses | SHANGHAI INST MATERIA MEDICA (CN) | 2006-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104558-A1 | Use of an EGFR Antagonist for the Treatment of Glomerolonephritis | EGFR, GCGR, PTPRJ | POLB 4754/4885TTBK1 3560/4885TTBK2 2753/4885 |
| US-20130289056-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | POLB 3762/4885TTBK1 2061/4885TTBK2 1851/4885 |
| US-20160287591-A1 | METHODS OF ADMINISTERING AN EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | POLB 3762/4885TTBK1 2061/4885TTBK2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.